Answers are grounded in this paper and cite their sources.
In vitro study demonstrates strong efficacy of voriconazole and itraconazole against drug-resistant Cryptococcus neoformans, highlighting viable alternative therapies for fungal infections.
In vitro susceptibility testing for 50 clinical isolates of fluconazole-susceptible or -resistant Cryptococcus neoformans was performed with itraconazole and voriconazole. Voriconazole was more potent than itraconazole for fluconazole-susceptible isolates and as potent as itraconazole for fluconazole-susceptible dose-dependent isolates and for fluconazole-resistant isolates. For fluconazole-resistant isolates, the voriconazole and itraconazole MICs ranged from 1 to 2 microg/ml.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: